培美曲塞用于晚期非鳞状非小细胞肺癌：关于其扩展应用及疗效的最新证据
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes.
作者信息
Tomasini Pascale, Barlesi Fabrice, Mascaux Celine, Greillier Laurent
机构信息
Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Multidisciplinary Oncology & Therapeutic Innovations, Marseille, France.
出版信息
Ther Adv Med Oncol. 2016 May;8(3):198-208. doi: 10.1177/1758834016644155. Epub 2016 May 9.
Abstract
Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and the treatment of advanced NSCLC relies on systemic treatments. During the last decade, pemetrexed, an antifolate agent, gradually became a key component of the treatment for patients with advanced nonsquamous NSCLC. It has indeed been shown to be efficient for first-line, maintenance and second- or third-line treatment in this subgroup of NSCLC. Moreover, it is usually well tolerated, with few grade 3 and 4 toxicities. Several studies have tried to identify predictive biomarkers of pemetrexed efficacy. Due to pemetrexed's mechanism of action, thymidilate synthase expression predictive value was investigated but could not be demonstrated. Currently, more than 400 trials of pemetrexed for the treatment of nonsquamous NSCLC are ongoing.
摘要
非小细胞肺癌（NSCLC）仍然是癌症相关死亡的主要原因，晚期NSCLC的治疗依赖于全身治疗。在过去十年中，抗叶酸剂培美曲塞逐渐成为晚期非鳞状NSCLC患者治疗的关键组成部分。确实已证明它对该亚组NSCLC的一线、维持及二线或三线治疗有效。此外，它通常耐受性良好，3级和4级毒性很少。多项研究试图确定培美曲塞疗效的预测生物标志物。由于培美曲塞的作用机制，对胸苷酸合成酶表达的预测价值进行了研究，但未得到证实。目前，有400多项关于培美曲塞治疗非鳞状NSCLC的试验正在进行。
相似文献
1
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes.培美曲塞用于晚期非鳞状非小细胞肺癌：关于其扩展应用及疗效的最新证据
Ther Adv Med Oncol. 2016 May;8(3):198-208. doi: 10.1177/1758834016644155. Epub 2016 May 9.
2
Pemetrexed in advanced non-small-cell lung cancer.培美曲塞治疗晚期非小细胞肺癌。
Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. doi: 10.1517/14656566.2010.482560.
3
Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed.根据组织类型定制非小细胞肺癌的治疗：培美曲塞的作用
Pharmgenomics Pers Med. 2009;2:21-37. doi: 10.2147/pgpm.s3977. Epub 2009 Jun 24.
4
5
Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.估计肌酐清除率与培美曲塞作为晚期非鳞状非小细胞肺癌延续维持治疗的疗效和毒性相关。
Clin Lung Cancer. 2015 Nov;16(6):e131-40. doi: 10.1016/j.cllc.2015.01.001. Epub 2015 Jan 10.
6
Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.预处理的 IIIB/IV 期非小细胞肺癌患者中组织学类型对培美曲塞疗效的影响：一项开放标签随机 II 期研究结果回顾。
J Thorac Oncol. 2009 Dec;4(12):1530-6. doi: 10.1097/JTO.0b013e3181b9e608.
7
Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.培美曲塞联合贝伐单抗用于老年晚期或复发性非鳞状非小细胞肺癌一线化疗的可行性研究：TORG1015
BMC Cancer. 2016 May 12;16:306. doi: 10.1186/s12885-016-2338-6.
8
Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.培美曲塞和顺铂联合西妥昔单抗治疗晚期非鳞状非小细胞肺癌患者的 II 期研究。
Lung Cancer. 2013 Sep;81(3):428-434. doi: 10.1016/j.lungcan.2013.05.010. Epub 2013 Jun 20.
9
Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.培美曲塞-铂类双药化疗联合或不联合贝伐珠单抗作为中国未经治疗的晚期非鳞状非小细胞肺癌患者一线治疗的疗效比较。
Clin Ther. 2019 Mar;41(3):518-529. doi: 10.1016/j.clinthera.2019.02.004. Epub 2019 Mar 4.
10
Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis.培美曲塞联合铂类双药化疗作为晚期非鳞状非小细胞肺癌一线治疗的疗效：一项系统评价和荟萃分析。
Onco Targets Ther. 2016 Mar 14;9:1471-6. doi: 10.2147/OTT.S96160. eCollection 2016.
引用本文的文献
1
Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment.揭示协同潜力：双特异性抗体联合化疗治疗晚期非小细胞肺癌
Curr Oncol. 2025 Mar 31;32(4):206. doi: 10.3390/curroncol32040206.
2
Polyol pathway-generated fructose is indispensable for growth and survival of non-small cell lung cancer.多元醇途径产生的果糖对非小细胞肺癌的生长和存活至关重要。
Cell Death Differ. 2025 Apr;32(4):587-597. doi: 10.1038/s41418-024-01415-1. Epub 2024 Nov 20.
3
Constructing a folate metabolism gene signature for predicting prognosis in pulmonary neuroendocrine carcinomas.构建用于预测肺神经内分泌癌预后的叶酸代谢基因特征。
J Cancer. 2024 Oct 14;15(19):6256-6272. doi: 10.7150/jca.102186. eCollection 2024.
4
Characterization of renal injury in non-squamous non-small cell lung cancer patients treated with pemetrexed: A single-center retrospective study.培美曲塞治疗非鳞状非小细胞肺癌患者肾损伤的特征：一项单中心回顾性研究。
Thorac Cancer. 2024 Dec;15(35):2474-2485. doi: 10.1111/1759-7714.15470. Epub 2024 Oct 29.
5
The Growth of A549 Cell Line is Inhibited by Pemetrexed Through Up-regulation of hsa-MiR-320a Expression.培美曲塞通过上调hsa-MiR-320a的表达抑制A549细胞系的生长。
Adv Biomed Res. 2024 Jul 29;13:50. doi: 10.4103/abr.abr_483_23. eCollection 2024.
6
Pembrolizumab therapy in a patient with NSCLC and bullous pemphigoid: A case report.帕博利珠单抗治疗非小细胞肺癌合并大疱性类天疱疮1例报告
Oncol Lett. 2024 Jul 31;28(4):470. doi: 10.3892/ol.2024.14603. eCollection 2024 Oct.
7
Pulmonary sarcomatoid carcinoma: A rare case report, diagnostic dilemma and review of literature.肺肉瘤样癌：一例罕见病例报告、诊断困境及文献复习。
Medicine (Baltimore). 2024 Jul 5;103(27):e38797. doi: 10.1097/MD.0000000000038797.
8
Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis.从 AACR NSCLC GENIE BPC 队列分析中深入了解 NSCLC 治疗特异性预后体细胞突变。
BMC Pulm Med. 2024 Jul 2;24(1):309. doi: 10.1186/s12890-024-03124-4.
9
Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations.阿替利珠单抗、贝伐单抗、卡铂和紫杉醇在现实世界中患有非小细胞肺癌且伴有EGFR或ALK改变的患者中的颅内疗效。
Cancers (Basel). 2024 Mar 22;16(7):1249. doi: 10.3390/cancers16071249.
10
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.氟嘧啶通过诱导免疫原性细胞死亡成为胸部恶性肿瘤免疫检查点抑制剂免疫最佳伙伴的潜力。
Thorac Cancer. 2024 Feb;15(5):369-378. doi: 10.1111/1759-7714.15200. Epub 2023 Dec 26.
本文引用的文献
1
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.胸苷酸合成酶表达作为晚期非小细胞肺癌培美曲塞敏感性的预测生物标志物。
BMC Pulm Med. 2015 Oct 26;15:132. doi: 10.1186/s12890-015-0132-x.
2
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.IV期非小细胞肺癌的全身治疗：美国临床肿瘤学会临床实践指南更新
J Clin Oncol. 2015 Oct 20;33(30):3488-515. doi: 10.1200/JCO.2015.62.1342. Epub 2015 Aug 31.
3
Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.非小细胞肺癌组织中EML4-ALK融合基因与胸苷酸合成酶mRNA表达之间的关联
Exp Ther Med. 2015 Jun;9(6):2151-2154. doi: 10.3892/etm.2015.2372. Epub 2015 Mar 19.
4
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.培美曲塞联合顺铂与吉西他滨联合顺铂治疗非鳞状非小细胞肺癌：根据胸苷酸合成酶表达的生物标志物分层随机 II 期试验。
J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.
5
Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.美国非鳞状非小细胞肺癌（NSCLC）一线诱导和维持治疗方案的成本效益
Lung Cancer. 2015 Sep;89(3):294-300. doi: 10.1016/j.lungcan.2015.05.020. Epub 2015 Jun 3.
6
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.尼妥珠单抗联合培美曲塞和顺铂一线治疗局部晚期或转移性非鳞状非小细胞肺癌患者（INSPIRE）：一项开放标签、随机、对照的 3 期研究。
Lancet Oncol. 2015 Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X. Epub 2015 Feb 18.
7
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.拉帕替尼与培美曲塞用于晚期或转移性非小细胞肺癌二线治疗的I期研究：评估循环游离胸苷酸合成酶RNA作为潜在生物标志物
Clin Lung Cancer. 2015 Sep;16(5):348-57. doi: 10.1016/j.cllc.2015.01.004. Epub 2015 Jan 20.
8
Global cancer statistics, 2012.全球癌症统计数据，2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
9
An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.一项开放标签、多中心、随机Ib/II期研究，对比甲磺酸艾瑞布林联合培美曲塞与单独使用培美曲塞作为晚期非鳞状非小细胞肺癌患者二线治疗的疗效。
Clin Lung Cancer. 2015 Mar;16(2):92-9. doi: 10.1016/j.cllc.2014.10.001. Epub 2014 Oct 15.
10
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.雷莫芦单抗联合培美曲塞和铂类化疗一线治疗非鳞状晚期/转移性非小细胞肺癌的 2 期、随机、开放标签研究。
Cancer. 2015 Mar 15;121(6):883-92. doi: 10.1002/cncr.29132. Epub 2014 Nov 6.
Zotero 插件